BioSpace News Archive

As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success Newly Disclosed Patient Level Data Demonstrates a 44% Best Overall Response for the HEPZATO Arm Versus 17% for the Best Alternative Care Arm Company Q&A Webinar Today at 8:30am ET

Ginkgo Bioworks, Inc. (“Ginkgo”) today announced the signing of a program in a partnership with the Sumitomo Chemical Co., Ltd . (“Sumitomo Chemical”), one of Japan’s leading chemical companies. Ginkgo is building the leading horizontal platform for cell programming, to serve customers across industries seeking to develop better products.

Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19—and inflammatory disorders, today announced that Brian Denomme, Co-Founder, previously Reven’s Chief Operating Officer will be stepping into a full-time role as the company’s President.

Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for a conditional marketing approval (CMA) for its COVID-19 vaccine in adolescents with the European Medicines Agency (EMA).

NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.

Acepodia, today announced that an article describing the efficacy profile of ACE1702, Acepodia’s novel, off-the-shelf natural killer (NK) cell therapy against HER2-expressing solid tumors, was published in the journal Cancers.

According to the report, the global stool secretory immunoglobulin A market was valued at ~US$ 27 Mn in 2019.

According to the report, the global nucleic acid extraction instruments & reagents market was valued at US$ 2.4 Bn in 2019.

The global industrial microbiology market is growing, thanks to the rising preference for industrial automation across the globe.

According to the report, the global hemoglobin feed market was valued at US$ 216.9 Mn in 2019 and is projected to expand at a CAGR of 4% from 2020 to 2030.